Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director John Kiely sold 50,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded up $0.88 during trading hours on Friday, hitting $18.15. The company had a trading volume of 2,006,321 shares, compared to its average volume of 2,167,094. Amneal Pharmaceuticals, Inc. has a 12 month low of $9.20 and a 12 month high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm’s fifty day moving average is $17.15 and its 200 day moving average is $14.56. The firm has a market capitalization of $5.79 billion, a price-to-earnings ratio of 37.04 and a beta of 1.27.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Rubric Capital Management LP increased its position in Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the period. Dimensional Fund Advisors LP lifted its position in Amneal Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after purchasing an additional 81,546 shares during the period. Morgan Stanley lifted its position in Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after purchasing an additional 1,315,018 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares during the last quarter. Finally, State Street Corp grew its position in shares of Amneal Pharmaceuticals by 3.4% during the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on AMRX shares. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. The Goldman Sachs Group restated a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Barclays raised their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.